
PD-1 pneumonitis Dataset analysis: Incidence, Risk Factors, Survival **Rational Page 2017 August 2018 **Banksperind august 1918** Description of a spile of following: The second of the se The anticology of the control of the mentant united to provide (s) [## (See All See All S And the second s Summary Statistics The data will pushy reasy gritting space. The collect heading are curdentname, and the factor leven for things like sex are not fined (for unitnown, seein M. Y and Y is a foreign - This means to be interested above type of and Y?) the sex is the push datagone policy promotive related and parenting leven from Cype Section 1. This is the database beginning or change of the database of parent promotive related to the push of the database beginning the related to the push of the database beginning the related to the push of the database beginning the related to the database of the dat E i de protesse una promotiona de la companya del la companya de la companya del la companya de la companya del la companya de la companya de

Smaking Status Current Former Never	a 2 2 2 5 6 6 6 7 6 7 7 7 7 7 7 7 7 7 7 7 7 7 7
d decising status appropriate (Coloniana)	or princes without Ri-1 premoties with the prince prince (being descentible security to the prince of the prince (being descentible security to the prince of the prince o
Smaking Status Current Former Never	a 133 133 133 133 133 133 133 133 133 13
	is all paints; Benking-Bertan, byslies (Benking-Bertann)EL dffEenking-Bertan), Fillelangth)
Smaking Status Current Former Never	# 55 55 55 55 55 55 55 55 55 55 55 55 55
# Canner Matelog	,
NSCLC Hestology Adenocarcinoma	in paintes all: PC: promonies LabedDECL.Matelogy, bytice(DECL.Matelogy) 1 2 3
Adenocationera Large cell neuroendoc Mesothelioma Psorty differentiated co	19 19 19 19 19 19 19 19 19 19 19 19 19 1
Squamous cell carcino # Canner Matrice appropria (Anthropology)	ma y in paintes school JO-1 promonitie mistabhalbette.Nesdong, bpiles BDEL dienzingvürbessmeistebesBBEL dienzing), Führlang
NSCLC Hessingy	X 556
Adenosquamous carci Atgpical cardnoid Carcinonia	tona 1
Mesothelioma Psorty differentiated co Sercomatoid carcinom	g seciona g a 1
Squamous cell carcino J. Canner Waterley, appropria (PSL_483)	ma 41 / Dates it all patients SCC. Minnings, Spriins (SCC. Minnings-POL #ESSCCL. Minnings), Fibringship
NSCLC Hessingy Adenocarcinoma Adenocquamous carci	322 132 1000a 1
Applical cardnoid Carcinoma Large cell neuroendoo	2 1 fore-cascinoma 5
Pacity differentiated co Serconatoid cardinon Siguamous cell cardino	
	potents with No.1 promotion this delicitation concentration. III. III. Tr., bytics (lotted Jacons Josep. I. II. III. III. Tr. obus incons.teapI. III. III. III. The Managan's incons.teapI. III. III. III. III. III. III. II
Initial Cancer Stage	ILLIAN X
1 1 10	1 5 10
F Cannor Minteling appropriate (Golvana obvassoministral)	promises without Rel promotion or patients without Rel promotion which believes in forces, the part of the little of the part of the little
Initial Cancer Stage	ALLEN X
# Canner Mattring apprepate (PGL ddE tal.Canner.Stage.	90 / Saran is all paints https://doi.org/10.111.111.117./pplint/batial.Communicage.fII.111.117.0000_6655as Lill.Lill.117.77./plintenphi
Initial Cancer Stage	
	1 12 52
J Personnilla Cra appropria (Personn menica Grade), F	936 in invasione in No-1 painose stitutullipus. Promonitis. Andre, kyrliss (Highwa. Promonitis. Andre Promonitis (Andre Promonitis) illustullipus. Promonitis. illustullipus. illustullipu
Highest Preumonitis	derante a 56
3 4 5 Linknown	0 2 2 5 5 1
S price elementes appregate (Pressum C. no. «Pressumonitia)	97 Hiddwillows, dar.initial.oreasement.i.pen.do.n., bpclist(Dawn, dar.initial.trantment.il.pen Publish.dor.initial.trantment.il.pen.down.), Thinteph)
Chemo for initial trea	Nachiman (America), (1984), (1
appropria (Golvana 8). en. ellebarran	mitiaPtaClhamo.for.initial.teratamatl.ym.,d.mo., Myslist(Damo.for.initial.teratamatl.ym mitiaPtaClhamo.for.initial.teratamatl.ym.,d.mo.), FEMilamph)
	Street, Eyes, Eric. + 0 Str. + 1 Str. +
-ggregate (PGL dd) -dd (Chemo , for , ini- Chemo for initial tree	Dome, for , initial , terriment , l.yer., f. se., priine (Dome, for , initial, terriment , l.yer., f. se., PHI initial to comment , l.yer., f. se., f. PHI initial to comment , l.yer., f. se., f. PHI initial to comment , l.yer., f. se., f. PHI initial to comment for the first first for the first firs
A point surpery approach the	1 150
Surgery for Initial too	STATEMENT OF THE CONTROL OF T
	1 2 miliabelDopey.for.Datai.vendemi.i.jps.d.m., kpriist@bopey.for.Datai.vendemi.i. miliabelDopey.for.Datai.vendemi.i.jps.d.m., // Philaphi miliabelDopey.for.Datai.vendemi.i.
Surgery for Initial two	19866f. Syek. J.Oo. a 5 127 1 41
appropria (PSL_ddT) sPSL_ddTStarpery.6	 45 Integery, for Johnson Community of the Commun
Surgery for Initial too	
I Cutomo of poou I no of patients : necu(PosumonitisP	moitis de recircul aiscrate (should be all) ([Seamont table[Harriste
## (1) 39 I this previous s	
J presentitio not apprepate (Present ed. 2. Depreved. 6.0 arteal, values are tia.Outcome. 1O 5. Normanno. C. Debn	
	C. C. Deproved. E. Worsered. actual values are 1. Completely Resolved 2 Improved 6. Stable Uncargo E.S. Worsered 8. Unknown
Improved Stable-Unchanged Unknown	
Warsened	hengy for pro 1123 promotion Lidd's Girar, 3.1-cardense, Johnson, Johnson, Johnson, Sprint (Flort, 33.1-cardense, Jointey, Inc. Memorials Hall From A. Jointessen, Johnson, Jones (April, 1986). The Committee of the Committee of Committee
First IO treatment. Pr MEDH738 10 inglig G	
Nicionals Pentroloumals	3
I type of Lemman appropriate (Software meanstherapy, Lyen) First 10 treatment. Pr	ereng ign der prinser stiten promotifie mitschafflen i Standamen, Frienzy Tomouthergy Agent, kyritist (Erst. (E. transmett., Frienzy I milleranna ist abraffren. D. transmett., Frienzy Tomouthergy Agent) / Filicia gibb (may Standament) Agent x
SAKS-606558 (MCX-11 Durvaturas)	1 2 4
MEDH736 10 mg/kg C MEDH736 20 mg/kg C Nivolumab POR001	of salesks 2 156 2
Penbroloumab Switch maintenance ni	21 volumedo 9
	nengy for all patients and all patients
BMS-606558 (MDX-11	05) 7 4
MEDH736 10 mg/kg C MEDH736 20 mg/kg C Nisolumab PDR001	2 1900 1900 2
Pembroloumab Switch maintenance to	ion therapy
	ins interegy promoted gits. O suppose the manifest plan. O suppose the manifest plans in the suppose
First IO 3 restrient Se	23
Azacitidine + CC486 + Azacitidine + Entinosta Carbopistin + Pacitase Ciepistin + Genotabin	
bilmunab	4



I lets look at I allow/ind in personnitie ve. no personnitie


presenting printer

approprie Personnitie interdition. Onter, litter i., lens (v., bprint (Wind. States, litter i., lens (v., break))

interdition. Litter i. Dead. (), Pübliopph)

Status Alivo 1 Dead 8

```
The second secon
               2. Model A: Cox PH for development of pneumonitis
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Strata
+ MatcChangel
+ MatcChangel
```



```
ali:
regh (formula = Sarv(PersonnitiaCrast, Personnitia)
Chamc = Combination.CCI, data = CombiNodal dd)
The state of the s
               100 mms. 200 mms. 200
```


```
**Constant part (

forming or of terming the part (**permutial and part of terming or of terming or of terming or of terming or of terming of terming of terming of terming or part (terming of terming of terming or part (terming of terming or terminal or ter
                     ([4])
(Seturoph) Chans
0.2186122 0.860824
                     ((9))
(Interruph) Surgery
0.2322222 0.8387143
     ## Deviance Residuals: ## Min 10 Nestian 30 Nestian ## Hin 10 Nestian 30 Nestian ## -0.6335 -0.4335 -0.4343 2.1165 ## Conflictments
```

```
The Management of the Manageme
                    A SALIMANIA SALI
                    Deviance Residuals:

No. 10 Notice No. No. No. 10 N
| Company | Comp
                                         printensing a forming, density a financial", dans a large financial financia
```







4. Model C: Cox PH Survival


Now, we run the Cas FM exceller collecting of death. These was the analysis persuscentile. Then, well-due is bentined, analysis for presuscentile. We are all the analysis of president with order of the analysis.

ex Race	Smoking Pi	Years .	Nive Death Or Last Follow U	p Histology	Initial Stage Sury	gery Radi	lation CI	neme Combination	JC1 Immunotherapy Start Date	Immunotherapy.Drug	Second immunotherapy Drug Preumo	nitis Pneumonitis.Gr	ade Preumonitis.Recurrent	Pneumonitis Outcome Pneumonitis SecondLin	eTx Pneumonitis.SecondLineOrug	age Pneumonitis	sOnset cer
tale B	- 1	56	0 5/15/2017	Adenocarcinoma		0	- 1	1	0 2012017	Nivolumab		1	2 No	Stable-Unchanged		63	15
eraie B	1	22	0.8802016	Adenocarcinom	-	1	0	1	1 1070014	Nivolumab	Azacitidne + CC486 + Entinostat (sequential)	1	2 No	Improved		62	239
emaie O	0	0	0 2/14/2017	Aderocarcinoma	· W	0	0	0	0 80500%	Nivolumab		1	2 No	Improved		75	4
Sale W	1	19	0 3010017	Squamous	N	0	0	0	0 7/18/2016	Penbroloumab		1	2 Yes	Improved		65	82
ble W	1	26	0 5000017	Squamous		0	1	1	0 2/14/2017	Nivolumab		1	5 No	Worsened		79	91
inte W	1	38	0 4950013	Squamous		1	1	4	1 8/1/2012	Nivolumab	Carbopiatin + Pacitasel	1	4 Yes	Improved		89	194
ale W	1	20	0 7/16/2011	Adenocarcinome	. W	0	0	1	0 6/17/2011	Nivolumab		1	5 No	Worsened	1 IMG/Inflainab	69	
ale W	2	49	0.680015	Squamous	N	0	0	1	0 5/7/2015	Nivolumab		1	5 No	Warsened		58	13
ale W	1	56	0 6000017	Adenocarcinoma	. W	0	0	0	1 6/12/2017	Nivolumab	Anti-LAGO	1	3 No	Improved	0	73	13
ale W	1		0 11000014	Squamous		0	1	1	0 2/6/2013	Nivolumab		1	3 No	Improved		84	12
de W	1	5	0 3/10017	Squamous		0	1	1	1 9303016	Nivolumab	Iplimumab	1	2 No	Improved		69	52
naie W	1	47	0 11/30/2016	Squamous	W	0	0	1	0 10282016	Nivolumab		1	5 No	Worsened	1 Infloresia	66	0
male B	1	41	0 1240014	Aderocarcinoma		1	0	0	1 3/10/2014	Nivolumab	Azacitidne - Entinostat (sequential)	1	3 No	Warsened		60	69
de W	1	28	0 6909017	Squamous		0	1	1	1 9303016	Nivolumab	lplimumab	1	3.0	2	0	67	197
male W	1	15	0 3979014	Aderocarcinoma	-	0	1	1	0 10/16/2013	MEDIA736 10 mg/kg Q2 weeks		1	2 No	Stable-Urchanged		63	23
maie W	0	0	0 12012011	Adenocarcinome	. W	0	0	1	0 10/10/2011	Nivolumab		1	3 No	Improved		69	17
ale W	0	0	0 5030019	Aderocarcinoma	. 1/	0	0	1	1 460015	Nivolumab	Azactidne - Entinostat (sequential)	1	2 No	Completely Resolved		64	108
ale W	1	24	0.58(2012	Squamous	W	0	0	1	1 12/19/2011	Nivolumab	Cispistin + Gerschsbine	1	3 Unknown	Unknown		75	112
ale W	1	54	0 5120013	Squamous		0	1	1	0 2010011	Nivolumab		1	5 Yes	Worsened		78	357
male W	0	0	0 8172019	Other		1	1	1	1 1060015	Nivolumab	Azactidne - Entinostat (sequential)	1	3 No	Improved		26	61
ale W	1	45	0 1/5/2015	Adenocarcinoma	. W	0	0	0	1 7040014	Nivolumab	Iplimumab	1	2 No	Improved		66	80
main B	1	20	0.702016	Adenocarcinoma	N N	0	0	0	1 1062014	Nivolumab	Iplimumab	1	2 No	Improved		75	525
ie W	1	37	0 5150016	Other		0	1	1	0 10500%	Nivolumab		1	2 No	Improved		74	30
male W	1	35	0.7030017	Adenocarcinoma	. W	0	0	0	0 7/16/2015	Nivolumab		1	3 Unknown	Improved		79	290
male W	- 1	16	0 12902019	Other					0 10/27/2016	Pentrolpumab		4	3.70	Unknown		71	35





To 20 20 20 20 40 400 24 - 27 - 20 - 270 - 20 - 400 - 10000 - 1000 - 1000 - 1000 - 1000 - 1000 - 1000 - 1000 - 1000 - 1000 1 2 2 20 20 20 40 600 1000




5b. Construction of Multi-State Model if (Fig. NEW dillay, Grade Jersonswitts . Y. I. E.G. [8] soil {
 if (Fig. NEW dillay, Grade Jersons it is . Jonetic. [8] soil {
 justices has no pronouncitie, is allow. This is state } I parties have a promotive, is alow. This is state 1 if from 1 if from 1 if the state 2 if from 1 if the state 3 if from 1 if the state 3 if the 3 if the 3 if the state 3 if the 3 if the state 3 if th # form :

(besists ("Mandd")) Handd <<- c|a,0,000 HES dff(besift) (besists)

Handd <<- shind(bloods, c|a,0,000 HES dff(besift) (besides), i Since [1] The man band processed layer, is stand, but depressed defines of layer, as 1-10, 2-12, 1-10 for processing the processing of














7 thed survival probability 0.2 0.4 0.9 0.8 1.1 From state 1
From state 2 From state 1 --- From state 1 ---- From state 2 From state 1
From state 2









Radiographic Data Analysis

	n dd (* med-ner("rede-dets.com") n dd fell (* leds jein/Rede dd, PersonnitiaPts, Spor("PersonnitiaPts.2000" n"600"), typen"ismer")
::	Marnings Column "Decembitis Pen-MOS" ("MOS" joining factor and character matter, constring into character vector
e un	mary(halo di fullilaterality)
::	Rileteral Rilateral Left K/G Right 1 16 1 5 2 12
mum.	mary(Nada_dd_full)Constitution(
::	8 Y 1 + 33
mum.	mary(Nada_66_6vil(SSS))
	8 Y 1 II 31
	mary(bade_dd_dullStepsal.shickening)
	W Y 1 M B
trum.	mary(Nade_dd_buillFourtion.homochiartamin)
	8 Y 1 H: 7
24.6	Ministro - hade di Fellifaca di fellifica di fellifica (). Ministro - hade di Fellifica di fellificani historia (mp. 7°,)[2] Ministro - hade di fellificato di fellificani historia (mp. 7°,)[2] pira [gista]
**	Leading supplied package: grints
::	Stanbing puckage: "gylinta"
::	The dillowing object is masked from 'package:state's
	point (Panali apran)
	Loading sequired package: Tembingsun
	Leading supplied parhage: grid
	Loading supplied parhage: futile.ingger
**	Interhing parhages "Resellagues"
	The delicating object is marked from 'packageoggpale's
	rotate









chi sq	-test(table(Confiding_dillnewmonitie, Confidenciallies))
	marson's Chi-uspared test with Tates' continuity correction
	Asc. takia ComPMHodel ddEPressensitis, ComPMHodel ddEStax
## 2	squared = 0.039811, of = 1, p-value = 0.8426
ohá se	rass(table(Craffilmia_dd)Personisis, Craffilmia_dd)Ress), similate.g.value(DEE)
**	
	taram's Chi-squared test with simulated p-value (based on 2000 militares)
**	
## de ## 25	ta: table(ConFMHodel ddEPensennitis, ConFMHodel ddEBare) mpasend = 0.55512, dd = NA, p-walse = 0.5125
ohi sq	-test(table(Confidence dilPossonnitis, Confidence dillocking), simulate.p.valuer(REE)
44 2	warson's Chi-appared test with similated p-value (based on 2000 uniforms)
**	
11 4	tar table(CosPMindel dd2Posumentis, CosPMindel dd2Empling) mganed = 0.791M, dd = MA, prysles = 0.7121
2	square v. cons, or a ma, pressed a v. con
ohi sq	test(table(CosMiddel dillhoumnnisis, CosMiddel dillistring), simulate.p.valuer[MID]
: -	terson's Chi-uppend test with simulated provide (bessed on 2000 spilatests) and telepicarMinist ASTPonomonists, Confidence of Simulatings)
# 2	squared = 0.3686, of = 35, p-value = 0.00149
obić so	test(table(CoeMHOdel_dd[Documentits, CoePHHOdel_dd[Initial.Stage), similate.g.valuer(MAE)
**	
	taram's Chi-squared test with simulated p-value (based on 2000 militares)
** .	tar table (Confidence dill'Assessation, Confidence dillinitial Chapp)
11 2	upared = 3.054, of = 16, p-value = 0.3853
	.test(table(CosMittal_dillNessensitis, CosMittals_dillChems), simulate.p.valuer(NIE)
	warson's Chi-equared test with similated p-value (based on 2001 splinates)
	tar takia/CorPNodei dilibusumenitia. CorPNbdei dilibumo
	equated = 0.07177, of = MA, p-value = 0.0312
ohi sq	. nan(table)CnoNNOtola_ddIPneumonitis, CnoPNOtola_ddIDnepery(, nimulate.p.valuerTRIE)
** :	waran's Chi-squared test with similated p-value (based on 2001 splinates)
**	
	ta: table(ConFMHodel dEFFennennitie, ConFMHodel dEFEnnenny)